Disease overview Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow plasma cells or …

Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to
10 years. MM progresses from the more common but often subclinical precursor states of …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Abstract African American/Black individuals have a disproportionate cancer burden,
including the highest mortality and the lowest survival of any racial/ethnic group for most …

Abstract In the United States, African American/black individuals bear a disproportionate
share of the cancer burden, having the highest death rate and the lowest survival rate of any …

Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma
(MM). Population-based screening for MGUS could identify candidates for early treatment in …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Monoclonal gammopathy of undetermined significance (MGUS) is, in many ways, a unique
hematologic entity. Unlike most hematologic conditions in which the diagnosis is intentional …

Multiple myeloma (MM) is a highly heterogenous disease that exists along a continuous
disease spectrum starting with premalignant conditions monoclonal gammopathy of …

Background Prevalence estimates for monoclonal gammopathy of undetermined
significance (MGUS) are based on predominantly White study populations screened by …